(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
· The newly approved device delivers a pre‑set 7.2 mg once weekly maintenance dose of semaglutide in a single injection. Previously, the 7.2 mg dose was administered by taking three 2.4 mg injections ...
The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results